Medical Developments International

ASX:MVP

FY26 ANNUAL GENERAL MEETING

12 November 2026



Important notice and disclaimer

This presentation contains summary information about Medical Developments International Limited (ACN 106340667) and its related bodies corporate (together, MVP) and MVP's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with MVP's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire MVP shares or other securities. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of MVP or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of MVP or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to MVP, including statements regarding MVP's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to MVP's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project," "intend", "outlook", "target", "assume" and "guidance" and other similar expressions. The forward-looking statements are based on MVP's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect MVP's business and operations in the future. MVP does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of MVP, that could cause the actual results, performances or achievements of MVP to be materially different to future results, performances or achievements expressed or implied by the statements.



Important notice and disclaimer

Factors that could cause actual results to differ materially include:

- the success of research and development activities (including clinical trials);
- decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims;
- competitive developments affecting our products;
- the ability to successfully market new and existing products;
- difficulties or delays in manufacturing;
- trade buying patterns and fluctuations in interest and currency exchange rates / general market conditions;
- legislation or regulations, particularly that affect product production, distribution, pricing, reimbursement, access or tax;
- litigation or government investigations; and
- MVP's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, MVP does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com

This presentation uses non-IFRS information including underlying revenue, underlying EBIT, underlying adjustments, gross margin and free cashflow. These measures are key performance measures used by MVP, the investment community, and peers with similar business portfolios. MVP uses these measures for its internal management reporting as it better reflects what MVP considers to be its underlying performance. Underlying revenue and EBIT are used to measure segment performance and have been extracted from the segment information disclosed in the FY24 Consolidated Financial Report.





Mark Fladrich

Company Chair

Your Board



Mark Fladrich
Company Chair



Russell Basser
Independent Non-executive Director



Paul Townsend
Independent Non-executive Director



Christine Emmanuel-Donnelly
Independent Non-executive Director



Leon Hoare
Independent Non-executive Director

Medical Developments International


How to ask a question

To ask a written question select the Q & A icon

Select the topic your question relates to from the drop-down list

Type your question in the text box and **press** the send icon

To ask a verbal question follow the instructions below the broadcast window.



Medical Developments International


How to vote

When the poll is open, select the vote icon at the top of the screen

To vote, select either For, Against or Abstain

You will see a vote confirmation

To change or cancel your vote “click here to change your vote” at any time until the poll is closed



Medical Developments International



Solid financial performance in FY26

Medical Developments International



Anita James

Interim CEO

FY26 Highlights

Solid financial performance, Penthrox® volume growth, key strategy milestones achieved

1 **Solid financial performance with strong cashflow generation**

Group revenue of $42.6m (+9%[1]); EBIT of $0.2m profit; Free cashflow of $4.2m improved by $5.8m; improved earnings in Pain Management and Respiratory segments

2 **Penthrox® volume growth in all regions**

In-market volume growth of 18% in Europe and 28% in Australian hospital segment

3 **Penthrox® addressable market expanded to children in Europe**

Expanded Penthrox® indication (from 18 years+ to 6 years+) approved and launched in UK and European markets

4 **Value proposition of Penthrox® strengthened with new health economic data**

Health economic study published demonstrating Penthrox® use in hospital emergency departments enables whole of department cost and operational savings compared with standard of care

5 **Targeted medical and commercial initiatives are supporting adoption and strengthening advocacy**

Penthrox adopted for use in IUD procedures in Women's Sexual and Reproductive Health Hubs in Victoria, access to Penthrox in the PBS Prescriber Bag extended to Nurse Practitioners

1. FY26 versus prior corresponding period. All growth numbers are against this benchmark unless otherwise stated

Medical Developments International

Priorities for FY27

Unlock value from the paediatric indication and accelerate Penthrox® expansion into high-growth markets and segments

1

Accelerate penetration of Penthrox

- Unlock value from the paediatric indication in Europe
- Utilise health economics analyses to accelerate adoption in the hospital segment in all geographies
- Generate additional real-world evidence to strengthen the clinical value and support adoption
- Strengthen partner engagement

2

Grow Penthrox® in new markets and segments

- Progress targeted entry into select new markets
- Evaluate opportunities for procedural indication expansion in Europe
- Continue broader market assessment of growth opportunities

3

Enhance margins and deliver operational efficiencies

- Continue to improve commercial terms to reflect the value proposition of Penthrox®
- Maintain disciplined cost management and deliver operational efficiencies

Medical Developments International

FY27 Outlook

FY26

Solid financial performance and progress of Strategy

- Solid cashflow generation
- Penthrox® volume growth in all regions
- Penthrox® paediatric label approved and launched in UK and European markets
- Health economic study completed demonstrating that Penthrox® use in hospital emergency departments enables whole of department cost and operational savings
- Strong balance sheet provides financial flexibility

FY27

Higher in-market Penthrox® demand

In FY27 we expect:

- Higher in-market Penthrox® demand, supported by the paediatric indication in Europe and the recently published health economic data;
- Stable demand in the Respiratory segment;
- Non-recurrence of Penthrox inventory stocking benefits reported in FY26; and
- Amortisation expense of ~$1 million related to capitalised registration costs for the European paediatric indication.

The impact to earnings of Middle East supply chain disruption and US tariffs remains uncertain and continues to be monitored.





Questions



Formal Business

Medical
Developments
International

Resolution 1

"That the Remuneration Report for the year ended 30 June 2026 as set out in the Company's Annual Report for the year ended 30 June 2026 be adopted."

Medical Developments International

Resolution 1 Proxy results

	For	Against	Open	Abstain
No. Of Shares	23,372,994	1,384,847	209,407	128,989
% of Total Proxies	93.61	5.55	0.84	NA

Medical Developments International

Resolution 2

"That pursuant to the Company's Constitution and for all other purposes, the members of the Company approve the re-election of Dr Russell Basser as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company's Constitution is retiring and being eligible offers himself for re-election."

Medical Developments International

Resolution 2 Proxy results

	For	Against	Open	Abstain
No. Of Shares	24,261,066	822,773	209,658	352,387
% of Total Proxies	95.91	3.26	0.83	NA

Medical Developments International

Resolution 3

"That pursuant to the Company's Constitution and for all other purposes, the members of the Company approve the re-election of Mr Paul Townsend as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company's Constitution is retiring and being eligible offers himself for re-election."

Medical Developments International

Resolution 3 Proxy results

	For	Against	Open	Abstain
No. Of Shares	24,252,725	831,114	209,658	352,387
% of Total Proxies	95.88	3.29	0.83	NA

Medical Developments International

Resolution 4

"That the shareholders approve the Company's new Rights Plan Rules for the purposes of ASX Listing Rule 7.2 Exception 13(b), sections 200B, 200E and 259B(2) of the Corporations Act and for all other purposes, as laid before the meeting, a copy of which is available for inspection at the registered office of the Company (during normal business hours)."

Medical Developments International

Resolution 4 Proxy results

	For	Against	Open	Abstain
No. Of Shares	23,052,313	1,686,037	209,658	148,229
% of Total Proxies	92.40	6.76	0.84	NA

Medical Developments International



Conclusion